Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Epithelial cell–derived cytokines: more than just signaling the alarm
Florence Roan, … , Kazushige Obata-Ninomiya, Steven F. Ziegler
Florence Roan, … , Kazushige Obata-Ninomiya, Steven F. Ziegler
Published April 1, 2019
Citation Information: J Clin Invest. 2019;129(4):1441-1451. https://doi.org/10.1172/JCI124606.
View: Text | PDF
Review Series

Epithelial cell–derived cytokines: more than just signaling the alarm

  • Text
  • PDF
Abstract

The epithelial cell–derived cytokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 are central regulators of type 2 immunity, which drives a broad array of allergic responses. Often characterized as “alarmins” that are released by the barrier epithelium in response to external insults, these epithelial cell–derived cytokines were initially thought to act only early in allergic inflammation. Indeed, TSLP can condition dendritic cells to initiate type 2 responses, and IL-33 may influence susceptibility to asthma through its role in establishing the immune environment in the perinatal lungs. However, TSLP, IL-33, and IL-25 all regulate a broad spectrum of innate immune cell populations and are particularly potent in eliciting and activating type 2 innate lymphoid cells (ILC2s) that may act throughout allergic inflammation. Recent data suggest that a TSLP/ILC axis may mediate steroid resistance in asthma. Recent identification of memory Th2 cell subsets that are characterized by high receptor expression for TSLP, IL-33, and IL-25 further supports a role for these cytokines in allergic exacerbations. There is therefore growing interest in developing biologics that target TSLP, IL-33, and IL-25. This Review provides an overview of TSLP, IL-33, and IL-25 and the development of blocking antibodies that target these epithelial cell–derived cytokines.

Authors

Florence Roan, Kazushige Obata-Ninomiya, Steven F. Ziegler

×

Figure 1

TSLP, IL-33, and IL-25 regulate a diversity of responses in type 2 immunity.

Options: View larger image (or click on image) Download as PowerPoint
TSLP, IL-33, and IL-25 regulate a diversity of responses in type 2 immun...
(A) IL-33 release in the lungs at birth helps establish the pulmonary immune environment, which can influence asthma risk and development later in life. (B) TSLP acts directly on DCs to drive Th2 cell development; IL-25, along with IL-4, can also drive Th2 cell differentiation. (C) TSLP, IL-33, and IL-25 act on a broad array of innate immune cells and are particularly important in eliciting and activating ILC2s; IL-25 can also elicit MPP type 2 cells and IL-17+ KLRG1hi cells. (D) TSLP and IL-33 can act on sensory neurons to stimulate the itch response. (E) TSLP, IL-33, and IL-25 can promote adaptive type 2 responses through subsets of memory Th2 cells that are characterized by high receptor expression for TSLP, IL-33, and IL-25.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts